Campath (alemtuzumab)

News alerts, weekly reports and conference planners

Company:

Bayer, Sanofi

Drug class:

CD52 inhibitor

Related drugs:

‹

ALLO-647 (0)

›

No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	alemtuzumab Sensitive: A1 - Approval alemtuzumab Sensitive : A1	alemtuzumab Sensitive: A1 - Approval alemtuzumab Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	rituximab + alemtuzumab Sensitive: A2 - Guideline rituximab + alemtuzumab Sensitive : A2	rituximab + alemtuzumab Sensitive: A2 - Guideline rituximab + alemtuzumab Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	rituximab + alemtuzumab Sensitive: A2 - Guideline rituximab + alemtuzumab Sensitive : A2	rituximab + alemtuzumab Sensitive: A2 - Guideline rituximab + alemtuzumab Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	rituximab + alemtuzumab Sensitive: A2 - Guideline rituximab + alemtuzumab Sensitive : A2	rituximab + alemtuzumab Sensitive: A2 - Guideline rituximab + alemtuzumab Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	rituximab + alemtuzumab Sensitive: A2 - Guideline rituximab + alemtuzumab Sensitive : A2	rituximab + alemtuzumab Sensitive: A2 - Guideline rituximab + alemtuzumab Sensitive : A2
No biomarker	Prolymphocytic Leukemia	No biomarker	Prolymphocytic Leukemia	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
CD52 expression	Prolymphocytic Leukemia	CD52 expression	Prolymphocytic Leukemia	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
Chr del(17)(p13.1)	Chronic Lymphocytic Leukemia	Chr del(17)(p13.1)	Chronic Lymphocytic Leukemia	alemtuzumab Sensitive: C3 – Early Trials alemtuzumab Sensitive : C3	alemtuzumab Sensitive: C3 – Early Trials alemtuzumab Sensitive : C3
Chr del(11)(q22.3)	Chronic Lymphocytic Leukemia	Chr del(11)(q22.3)	Chronic Lymphocytic Leukemia	alemtuzumab Sensitive: C3 – Early Trials alemtuzumab Sensitive : C3	alemtuzumab Sensitive: C3 – Early Trials alemtuzumab Sensitive : C3
CD123 positive	Acute Myelogenous Leukemia	CD123 positive	Acute Myelogenous Leukemia	alemtuzumab + UCART123 Sensitive: C3 – Early Trials alemtuzumab + UCART123 Sensitive : C3	alemtuzumab + UCART123 Sensitive: C3 – Early Trials alemtuzumab + UCART123 Sensitive : C3
CDKN2A deletion	Prolymphocytic Leukemia	CDKN2A deletion	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
STAT5B N642H	Prolymphocytic Leukemia	STAT5B N642H	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
TCL1A rearrangement	Prolymphocytic Leukemia	TCL1A rearrangement	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
RAD50 Y625	Prolymphocytic Leukemia	RAD50 Y625	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
ATM D2721N	Prolymphocytic Leukemia	ATM D2721N	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
PAK4 deletion	Prolymphocytic Leukemia	PAK4 deletion	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
BRAF V600E	Prolymphocytic Leukemia	BRAF V600E	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
Chr del(13)(q14)	Chronic Lymphocytic Leukemia	Chr del(13)(q14)	Chronic Lymphocytic Leukemia	alemtuzumab Sensitive: C4 – Case Studies alemtuzumab Sensitive : C4	alemtuzumab Sensitive: C4 – Case Studies alemtuzumab Sensitive : C4
MYC rearrangement + BCL2 rearrangement	Non-Hodgkin’s Lymphoma	MYC rearrangement + BCL2 rearrangement	Non-Hodgkin’s Lymphoma	ibrutinib + alemtuzumab Sensitive: D – Preclinical ibrutinib + alemtuzumab Sensitive : D	ibrutinib + alemtuzumab Sensitive: D – Preclinical ibrutinib + alemtuzumab Sensitive : D

Campath (alemtuzumab)

Associations
(25)

Associations
(25)

Campath (alemtuzumab)

Associations(25)

Associations(25)

Associations
(25)

Associations
(25)